Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun:155:107375.
doi: 10.1016/j.vph.2024.107375. Epub 2024 Apr 24.

Inferior vena cava filters: Concept review and summary of current guidelines

Affiliations
Review

Inferior vena cava filters: Concept review and summary of current guidelines

Luca Visconti et al. Vascul Pharmacol. 2024 Jun.

Abstract

Anticoagulation is the first-line approach in the prevention and treatment of pulmonary embolism. In some instances, however, anticoagulation fails, or cannot be administered due to a high risk of bleeding. Inferior vena cava filters are metal alloy devices that mechanically trap emboli from the deep leg veins halting their transit to the pulmonary circulation, thus providing a mechanical alternative to anticoagulation in such conditions. The Greenfield filter was developed in 1973 and was later perfected to a model that could be inserted percutaneously. Since then, this model has been the reference standard. The current class I indication for this device includes absolute contraindication to anticoagulants in the presence of acute thromboembolism and recurrent thromboembolism despite adequate therapy. Additional indications have been more recently proposed, due to the development of removable filters and of progressively less invasive techniques. Although the use of inferior vena cava filters has solid theoretical advantages, clinical efficacy and adverse event profile are still unclear. This review analyzes the most important studies related to such devices, open issues, and current guideline recommendations.

Keywords: Anticoagulants; Inferior vena cava filters; Interventional radiology; Pulmonary embolism.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Grant FOR READINGS/SPEECHES AT CONFERENCES: Chiesi, GSK, Firma, Guidotti, Sanofi, Astrazeneca. Project with drug development: Chiesi and Astrazeneca. Project without drug development: GSK.

References

Publication types

MeSH terms